These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32299860)

  • 1. The effect of exacerbation history on outcomes in the IMPACT trial.
    Halpin DMG; Dransfield MT; Han MK; Jones CE; Kilbride S; Lange P; Lipson DA; Lomas DA; Martinez FJ; Pascoe S; Singh D; Wise R; Criner GJ
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32299860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
    Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
    Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
    Ismaila AS; Risebrough N; Schroeder M; Shah D; Martin A; Goodall EC; Ndirangu K; Criner G; Dransfield M; Halpin DM; Han MK; Lomas DA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2681-2695. PubMed ID: 31819401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
    Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
    Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
    Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
    Singh D; Maleki-Yazdi MR; Tombs L; Iqbal A; Fahy WA; Naya I
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1413-24. PubMed ID: 27445468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
    Panettieri RA; Camargo CA; Cheema T; El Bayadi SG; Fiel S; Vila TM; Jain RG; Midwinter D; Thomashow B; Ludwig-Sengpiel A; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2043-2052. PubMed ID: 36072608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J; Zhong N; Newlands A; Church A; Goh AH
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
    Zheng J; Zhong N; Wang C; Wei LP; Zhou XD; Zhao L; Dong Yuan Y; He B; Wu B; Du X; Song J; Lipson DA
    Curr Med Res Opin; 2021 Jan; 37(1):145-155. PubMed ID: 33124900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
    Beeh KM; Rothnie KJ; Claussen J; Hardtstock F; Knapp RK; Wilke T; Czira A; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
    Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
    Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of baseline COPD symptom severity on the benefit from dual
    Vogelmeier CF; Kerwin EM; Bjermer LH; Tombs L; Jones PW; Boucot IH; Naya IP; Lipson DA; Compton C; Barnes N; Maltais F
    Ther Adv Respir Dis; 2020; 14():1753466620968500. PubMed ID: 33167780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.